This is a StreetInsider.com Premium Only Page

XOMA (XOMA) – Company Press Releases

Apr 3, 2024 09:00 AM XOMA Corporation Announces Closing of Tender Offer

Mar 21, 2024 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Mar 8, 2024 07:30 AM XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Feb 28, 2024 07:30 AM XOMA to Present at Upcoming Investor Conferences in March

Feb 16, 2024 08:00 AM XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Jan 18, 2024 08:30 AM XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Jan 11, 2024 04:05 PM FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

Jan 9, 2024 08:00 AM LadRx Issues 2024 Update to Shareholders

Jan 8, 2024 07:30 AM XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

Jan 2, 2024 07:30 AM XOMA Announces Stock Repurchase Program of up to $50 Million

Dec 20, 2023 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Dec 19, 2023 07:30 AM XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Nov 7, 2023 07:30 AM XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Oct 31, 2023 07:30 AM XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Sep 25, 2023 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Sep 6, 2023 07:30 AM XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 8, 2023 07:30 AM XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Jun 23, 2023 06:14 PM XOMA Added to the Russell 2000® and Russell 3000® Indexes

Jun 22, 2023 07:30 AM XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

Jun 22, 2023 07:30 AM LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

Jun 20, 2023 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

May 9, 2023 07:30 AM XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

Apr 26, 2023 07:30 AM XOMA to Present at H.C. Wainwright BioConnect Investor Conference

Apr 26, 2023 07:30 AM XOMA to Present at H.C. Wainwright BioConnect Investor Conference

Mar 30, 2023 07:30 AM XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

Mar 30, 2023 07:30 AM XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

Mar 21, 2023 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Mar 21, 2023 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Mar 9, 2023 07:30 AM XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

Mar 9, 2023 07:30 AM XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

Feb 28, 2023 07:30 AM XOMA to Present at 43rd Annual Cowen Health Care Conference

Feb 28, 2023 07:30 AM XOMA to Present at 43rd Annual Cowen Health Care Conference

Jan 6, 2023 07:00 PM XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2023 07:30 AM New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy

Dec 22, 2022 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Nov 22, 2022 07:01 AM XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

Nov 3, 2022 07:30 AM XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events

Sep 21, 2022 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Sep 7, 2022 07:30 AM XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 4, 2022 07:30 AM XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

Jun 20, 2022 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Jun 2, 2022 01:00 AM Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

May 17, 2022 04:05 PM XOMA to Present at H.C. Wainwright Global Investment Conference

May 5, 2022 07:30 AM XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

Mar 21, 2022 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends

Mar 10, 2022 07:30 AM XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Mar 8, 2022 07:30 AM XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

Mar 1, 2022 07:30 AM XOMA to Present at the 42nd Annual Cowen Health Care Conference

Feb 17, 2022 07:30 AM XOMA to Present at Aegis Capital Corp Investor Conference

Dec 23, 2021 07:30 AM XOMA Declares Quarterly Preferred Stock Dividends